In advance of the annual ARA meeting next month, abstracts of clinical trials being presented are likely to be published next week in the October issue of Arthritis and Rheumatism, the ARA's research journal. I expect the VX 509 data in RA in combination with MTX will be positive, and hopefully so will the study looking at MRI of joints in RA patients treated with VX 509 as well. Perhaps we'll get an announcement on the licensing/co-development deal that Vertex execs have been seeking to expedite the development of VX 509 in multiple autoimmune diseases.
With all due respect, how many times has a post with this basic message been posted here? An investor conference or earnings announcement is due and up pop the usual posts of impending VX-509 and VX-787 data and/or partnership announcements. Like waiting for Godot and the joke is on the investors. I hope you're right but history says this management team just can't deliver in a timely manner.